CARB-X is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibiotics, preventatives, rapid diagnostics and other products. CARB-X is the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials.
ESCMID is the leading Society for Clinical Microbiology and Infectious Diseases in Europe. ESCMID is proud to unite 12K members as well as 45K affiliated members through 77 national and international affiliated societies. In the wake of the COVID-19 pandemic, ESCMID now plays an important role in emerging infectious diseases and antimicrobial resistance education and research.
GARDP accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
BEAM Alliance was created in 2016 to carry the voice of Small and Medium Enterprises (SMEs) innovating against AntiMicrobial Resistance (AMR). BEAM works together with stakeholders to shape policies that can improve research and development in the AMR field. BEAM Alliance members develop a wide range of solutions across three key areas: prevention, diagnosis, and treatment of antibiotic-resistant infections.
LifeArc is a not-for-profit life science organisation leading the way for change in rare diseases and supporting promising initiatives in global health. LifeArc funds, collaborates and provides scientific expertise to improve the lives of people with rare diseases and in global health. LifeArc collaborates with others already working in these areas to create better tests, treatments and cures by providing investment, expert scientific support and commercialisation advice.
Antimicrobial Resistance Solutions is a newsletter that delivers the latest about antibiotics and antimicrobials to your inbox. Curated by John H. Rex, MD, the aim of this newsletter is to encourage the global efforts of new agent development.
Boston University (BU) is a prominent research institution in Boston, Massachusetts, focusing on health sciences and public health. It conducts significant research on antimicrobial resistance (AMR) through its School of Public Health and Medical Campus, examining resistance mechanisms, antibiotic misuse, and strategies to combat AMR. BU collaborates with various organizations to promote responsible antibiotic use, making it a key player in addressing this global health challenge.
Would you like to receive news about GAMRIC to stay up to date? Then subscribe to our newsletter.
Please note that you will receive an email from ESCMID asking you to confirm your newsletter registration. Your registration will only be active after your confirmation.